ADMA Biologics Inc (ADMA) has disclosed a new risk, in the Regulation category.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ADMA Biologics Inc. faces significant business risks that could impact its stock value, as highlighted in their quarterly report. The summary of risk factors indicates that investing in their common stock is speculative due to various principal factors. These risks are detailed further in the report under ‘Risk Factors’ and should be reviewed alongside other information provided. Investors are advised to carefully consider these risks before making investment decisions.
Overall, Wall Street has a Moderate Buy consensus rating on ADMA stock based on 2 Buys.
To learn more about ADMA Biologics Inc’s risk factors, click here.